473 results on '"de Souza, Carmino A."'
Search Results
2. Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma
3. Effects of a physiotherapeutic protocol in cardiorespiratory, muscle strength, aerobic capacity and quality of life after hematopoietic stem cell transplantation
4. Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study
5. Correction of Intensity of Bone Involvement (IBI) Index by Lean Body Mass and Body Surface Area
6. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project
7. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
8. Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
9. Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
10. CML-425 Evaluation of Antibody Responses among Five Different SARS-Cov-2 Vaccines in Chronic Myeloid Leukemia (CML) Patients – A Real-World Study
11. POSTER: CML-425 Evaluation of Antibody Responses among Five Different SARS-Cov-2 Vaccines in Chronic Myeloid Leukemia (CML) Patients – A Real-World Study
12. P1199: CLINICAL UPSHOTS OF PIONEER PROJECT TO COLLECT DATA OF T-CELL NHL PATIENTS AMONG FIVE REGIONS OF BRAZIL. T-CELL BRAZIL PROJECT.
13. PB1977: EVALUATION OF ANTIBODY RESPONSES AMONG FIVE DIFFERENT SARS-COV-2 VACCINES IN CHRONIC MYELOID LEUKEMIA PATIENTS – A REAL-WORLD STUDY
14. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
15. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma
16. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
17. Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients
18. Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma
19. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience
20. T084: Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
21. P018: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
22. HOW I TREAT DOUBLE-HIT LYMPHMOMA AND HGBL, NOS
23. AN UPDATED OF PIONEER PROJECT TO COLLECT DATA OF T-CELL NHL PATIENTS AMONG FIVE REGIONS OF BRAZIL. T-CELL BRAZIL PROJECT
24. Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: Report from the prospective international T‐cell lymphoma project
25. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
26. Impairment of thrombin generation in the early phases of the host response of sepsis
27. Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry
28. Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma.
29. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
30. Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw
31. Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
32. The Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and its absolute commitment to ethics and absence of conflicts of interest
33. Metabolic Volume Measurements in Multiple Myeloma
34. Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor
35. CURRENT THERAPY FOR INDOLENT LYMPHOMAS
36. Effects of a physiotherapeutic protocol in cardiorespiratory, muscle strength, aerobic capacity and quality of life after hematopoietic stem cell transplantation
37. BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution
38. Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis
39. Peripheral oxygen measurements in suspected elderly COVID-19 patients can be an effective tool for alerting physicians
40. COVID-19 in chronic myeloid leukemia patients in Latin America
41. The Brazilian Association of Hematology, Hemotherapy and Cellular Therapy seeks the implementation of, and access to, the CAR-T cell treatment in Brazil
42. Tyrosine Kinase Inhibitor Withdrawal Syndrome in Chronic Myeloid Leukemia Patients Participants of Two Discontinuation Clinical Trials
43. External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry
44. Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission
45. Predictive Value of BCR::ABL1 Transcripts Kinetics in the Molecular Relapse of Chronic Myeloid Leukemia Patients after Tyrosine Kinase Inhibitors Discontinuation: Results from the DES-CML Study
46. Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America
47. AUTOLOGOUS HEMATOPOIETC CELL TRANSPLANTATION (HCT) FOR HODGKIN LYMPHOMA, REAL WORLD EXPERIENCE OF A SINGLE CENTER EXPERIENCE
48. THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT
49. Treatment Of Classical Hodgkin Lymphoma: The State Of The Art
50. Polymorphisms of methylenetetrahydrofolate reductase ( MTHFR), methionine synthase ( MTR), methionine synthase reductase ( MTRR), and thymidylate synthase ( TYMS) in multiple myeloma risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.